2016-10-01
Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR
Publication
Publication
Annals of Oncology , Volume 27 p. vi313
Additional Metadata | |
---|---|
doi.org/10.1093/annonc/mdw375.01, hdl.handle.net/1765/125578 | |
Annals of Oncology | |
Organisation | Department of Hematology |
Weisel, K., Palumbo, A., Chanan-Khan, A. A., Nooka, A., Spicka, I., Masszi, T., … Sonneveld, P. (2016). Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR. Annals of Oncology, 27. doi:10.1093/annonc/mdw375.01 |